&nbsp;

GEMCNPAC(W).pdf

May 2020

Document

GEMCNPAC(W)-FR.pdf

Jun 2020

Regimen

GEMOD

Cancer Type:

Hematologic,

Lymphoma - T-cell

Intent: Adjuvant, Curative, Palliative

Funding:

ODB - General Benefit

dexamethasone

Drugs Used:

Quick Link(s):

Regimen Monograph

Dec 2020

Regimen

GEMOX

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Palliative, Curative, Adjuvant

Drugs Used:

gemcitabine,

oxaliplatin

Quick Link(s):

Regimen Monograph

Dec 2020

Regimen

GEMOX+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Palliative, Curative, Adjuvant

Drugs Used:

riTUXimab (Unfunded),

gemcitabine,

oxaliplatin,

riTUXimab (subcut) (Unfunded)

Quick Link(s):

Regimen Monograph

Feb 2021

Regimen

GEMOX

Cancer Type:

Endocrine,

Thyroid

Intent: Palliative

Drugs Used:

gemcitabine,

oxaliplatin

Quick Link(s):

Regimen Monograph

Dec 2020

Neuroendocrine Tumours (NETs)

Regimen

NIVL+IPIL(MNT)

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - In Combination with Platinum Doublet Chemotherapy for First Line Metastatic or Recurrent Non-Small Cell Lung Cancer

New Drug Funding Program

Nivolumab plus Ipilimumab - In Combination with Platinum Doublet Chemotherapy for First Line Metastatic or Recurrent Non-Small Cell Lung Cancer

Drugs Used:

nivolumab,

ipilimumab

Quick Link(s):

Regimen Monograph

Nov 2024

Document

NursingPracticeContinuum.pdf

Jun 2021

Regimen

NIVL(MNT)

Cancer Type:

Skin,

Melanoma

Intent: Adjuvant

Drugs Used:

nivolumab (Unfunded)

Quick Link(s):

Regimen Monograph

Aug 2024

Goals of Care Toolkit for Oncology Settings

Document